Drug Profile
DTaP vaccine - Beijing Minhai Biotechnology
Alternative Names: Diphtheria tetanus-acellular pertussis vaccine - Beijing Minhai BiotechnologyLatest Information Update: 19 Nov 2018
Price :
$50
*
At a glance
- Originator Beijing Minhai Biotechnology
- Developer Beijing Minhai Biotechnology; Jiangsu Provincial Center for Disease Control and Prevention
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diphtheria; Pertussis; Tetanus
Most Recent Events
- 19 Nov 2018 No recent reports of development identified for phase-III for Diphtheria (In infants, Prevention) in China (Parenteral)
- 19 Nov 2018 No recent reports of development identified for phase-III for Pertussis (In infants, Prevention) in China (Parenteral)
- 19 Nov 2018 No recent reports of development identified for phase-III for Tetanus (In infants, Prevention) in China (Parenteral)